Manulife (Manufacturers Life Insurance)’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-132,817
| Closed | -$6.31M | – | 2855 |
|
|
2025
Q3 | $6.31M | Sell |
132,817
-6,017
| -4% | -$291K | 0.01% | 1079 |
|
|
2025
Q2 | $7.41M | Sell |
138,834
-12,456
| -8% | -$566K | 0.01% | 985 |
|
|
2025
Q1 | $6.12M | Buy |
151,290
+26,698
| +21% | +$1.13M | 0.01% | 1075 |
|
|
2024
Q4 | $3.47M | Buy |
124,592
+28,043
| +29% | +$849K | ﹤0.01% | 1343 |
|
|
2024
Q3 | $2.77M | Sell |
96,549
-10,623
| -10% | -$277K | ﹤0.01% | 1435 |
|
|
2024
Q2 | $2.51M | Buy |
107,172
+22,195
| +26% | +$475K | ﹤0.01% | 1429 |
|
|
2024
Q1 | $2.15M | Buy |
84,977
+13,952
| +20% | +$335K | ﹤0.01% | 1494 |
|
|
2023
Q4 | $1.66M | Sell |
71,025
-5,588
| -7% | -$110K | ﹤0.01% | 1542 |
|
|
2023
Q3 | $3.88M | Buy |
76,613
+12,183
| +19% | +$567K | ﹤0.01% | 1223 |
|
|
2023
Q2 | $3.01M | Buy |
64,430
+6,772
| +12% | +$310K | ﹤0.01% | 1284 |
|
|
2023
Q1 | $2.21M | Buy |
57,658
+2,415
| +4% | +$108K | ﹤0.01% | 1375 |
|
|
2022
Q4 | $2.99M | Buy |
55,243
+31,417
| +132% | +$1.35M | ﹤0.01% | 1283 |
|
|
2022
Q3 | $761K | Buy |
23,826
+11,342
| +91% | +$174K | ﹤0.01% | 1729 |
|
|
2022
Q2 | $118K | Buy |
12,484
+863
| +7% | +$9K | ﹤0.01% | 2856 |
|
|
2022
Q1 | $165K | Sell |
11,621
-2,548
| -18% | -$44.6K | ﹤0.01% | 2838 |
|
|
2021
Q4 | $302 | Sell |
14,169
-213
| -1% | -$4.72K | ﹤0.01% | 2600 |
|
|
2021
Q3 | $321K | Sell |
14,382
-878
| -6% | -$19.9K | ﹤0.01% | 2608 |
|
|
2021
Q2 | $379K | Buy |
15,260
+6,731
| +79% | +$189K | ﹤0.01% | 2625 |
|
|
2021
Q1 | $247K | Sell |
8,529
-295
| -3% | -$8.93K | ﹤0.01% | 2749 |
|
|
2020
Q4 | $228K | Buy |
8,824
+907
| +11% | +$25.2K | ﹤0.01% | 2697 |
|
|
2020
Q3 | $244K | Buy |
+7,917
| New | +$277K | ﹤0.01% | 2437 |
|
Other funds holding AKRO
Manulife (Manufacturers Life Insurance)'s AKRO Position: Q4 2025 in Review
Manulife (Manufacturers Life Insurance) sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 132,817 shares — an estimated $6.31M sold.
Manulife (Manufacturers Life Insurance) first reported a position in AKRO in Q3 2020 and held it in 21 quarters. The position peaked at $7.41M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Manulife (Manufacturers Life Insurance) reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Manulife (Manufacturers Life Insurance) sold 132,817 Akero Therapeutics shares in Q4 2025, an estimated $6.31M.
- Manulife (Manufacturers Life Insurance) first reported a position in Akero Therapeutics in Q3 2020 and held it in 21 quarters.
- Manulife (Manufacturers Life Insurance)'s Akero Therapeutics position peaked at $7.41M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2025, filed 13 Feb 2026.